Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • Praxis Precision Medicines' Cash from Financing Activities rose 37047.35% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.4 million, marking a year-over-year decrease of 4973.29%. This contributed to the annual value of $514.3 million for FY2024, which is 45983.17% up from last year.
  • Per Praxis Precision Medicines' latest filing, its Cash from Financing Activities stood at $6.8 million for Q3 2025, which was up 37047.35% from $28.6 million recorded in Q2 2025.
  • Over the past 5 years, Praxis Precision Medicines' Cash from Financing Activities peaked at $216.4 million during Q2 2024, and registered a low of $504000.0 during Q2 2022.
  • In the last 4 years, Praxis Precision Medicines' Cash from Financing Activities had a median value of $12.4 million in 2023 and averaged $50.5 million.
  • In the last 5 years, Praxis Precision Medicines' Cash from Financing Activities surged by 1372440.48% in 2023 and then crashed by 8676.76% in 2025.
  • Quarter analysis of 4 years shows Praxis Precision Medicines' Cash from Financing Activities stood at $5.4 million in 2022, then decreased by 23.41% to $4.1 million in 2023, then soared by 2657.32% to $113.8 million in 2024, then tumbled by 94.06% to $6.8 million in 2025.
  • Its Cash from Financing Activities was $6.8 million in Q3 2025, compared to $28.6 million in Q2 2025 and $54.3 million in Q1 2025.